Sign up for our complimentary
weekly e-journal

Main Newsletter
Mastery Series
Therapy Series
 
Bookmark and Share | Print Article | Items for the Week Previous | All Articles This Week | Next
This article originally posted and appeared in  Type 2 DiabetesGenetics of DiabetesIssue 729

Circulating MicroRNAs Associated with Type 2 Diabetes

Researchers identified increases in three miRNAs and decreases in seven miRNAs in patients with type 2 diabetes…. 

Advertisement

Francisco J. Ortega, Ph.D., and colleagues from the Institut d'Investagacio Biomedica de Girona in Spain studied circulating miRNA in 12 men, six of whom had normal glucose tolerance and the other six who had type 2 diabetes. The association of 10 circulating miRNAs with type 2 diabetes was also verified cross-sectionally in another sample of 45 men with normal glucose tolerance and 48 men with type 2 diabetes. A longitudinal validation was carried out in 35 patients with type 2 diabetes in a randomized, three month long metformin trial. Furthermore, circulating miRNAs were studied in seven healthy participants before and after a six hour hyperinsulinemic-euglycemic clamp and insulin plus intralipid/heparin infusion.

Researchers identified increases in three miRNAs and decreases in seven miRNAs in patients with type 2 diabetes. They found that miR-140-5p and miR-423-5p independently accounted for 49.5% of fasting glucose variance after controlling for confounders. These two specific miRNAs along with miR-195 and miR-126 were specific for type 2 diabetes with 89.2% accuracy. Significant reduction in fasting glucose, glycated hemoglobin, and changes in circulating miR-192, miR-140-5p, and miR-22 were seen with metformin but not placebo. Reduction in miR-222 was seen with insulin infusion during clamp, while increases in circulating miR-222 and miR-140-5p were seen with the intralipid/heparin mixture. These results show that there is a close association between circulating miRNAs and type 2 diabetes.

Practice Pearls:
  • Levels of circulating miRNAs vary with insulin action
  • There is an association between circulating miRNAs and type 2 diabetes as they may play a potentially important role in insulin sensitivity

"Circulating MicroRNAs Linked to Type 2 Diabetes."  http://www.ncbi.nlm.nih.gov/pubmed/24478399

Advertisement


 

Bookmark and Share | Print | Category | Home

This article originally posted 16 May, 2014 and appeared in  Type 2 DiabetesGenetics of DiabetesIssue 729

Past five issues: Diabetes Clinical Mastery Series Issue 247 | Issue 787 | Diabetes Clinical Mastery Series Issue 246 | SGLT-2 Inhibitors Special Edition June 2015 | Issue 786 |

2015 Most Popular Articles:

Triple Therapy Improves Glycemia in Type 1 Diabetes
Posted June 19, 2015
A Dual SGLT1/SGLT2 Inhibitor Can be a Treatment Option in Type 1 Diabetics
Posted June 12, 2015
Canagliflozin and Its Effects on Weight Loss and BP
Posted June 12, 2015
High Fiber Diets Reduce Risk of Diabetes
Posted June 04, 2015
Efficacy and Safety of an SGLT-2 Inhibitor with Insulin for Type 2s
Posted May 28, 2015
Skin Bacteria a Cause of Diabetes?
Posted June 12, 2015
Blood Biomarkers May Predict Risk of Severe Hypoglycemia
Posted June 12, 2015
Are Postprandial Levels in T1 Patients Impacted by More Than Carbohydrates?
Posted May 28, 2015
Lilly Insulin: A Better Alternative than Lantus?
Posted June 19, 2015
Tight Blood Glucose Control and Cardiovascular Disease
Posted June 12, 2015


Browse by Feature Writer & Article Category.
A. Lee Dellon, MD | Aaron I. Vinik, MD, PhD, FCP, MACP | Beverly Price | Charles W Martin, DD | Derek Lowe, PhD | Dr. Brian Jakes, Jr. | Dr. Fred Pescatore | Dr. Tom Burke, Ph.D | Eric S. Freedland | Evan D. Rosen | Ginger Kanzer-Lewis | Greg Milliger | Kristina Sandstedt | Laura Plunkett | Leonard Lipson, M.A. | Louis H. Philipson | Maria Emanuel Ryan, DDS, PhD | Marilyn Porter, RD, CDE | Melissa Diane Smith | Michael R. Cohen, RPh, MS, ScD, FASHP | Paul Chous, M.A., OD | Philip A. Wood PhD | R. Keith Campbell, Professor, B.Pharm, MBA, CDE | Richard K. Bernstein, MD | Sheri R. Colberg PhD | Sherri Shafer | Stanley Schwartz, MD, FACP, FACE | Steve Pohlit | Steven V. Edelman, M.D. | Timothy S. Hollingshead |

Cast Your Vote
Have you recommended the use of an SGLT-2 inhibitor to any of your type 1 patients?

CME/CE of the Week
Warren Joseph, DPM, FIDSA

Category: Wound Care
Credits: .75